Objective: To compare pitavastatin 4 mg (high dose) with 2 (moderate and ezetimibe combination on LDL-C in type II diabetics. Study Design: Setting: National Medical Center (NMC) PNS Shifa Hospital. Period: January June 2022. Material & Methods: Fifty diagnosed diabetics metformin, 25 the monotherapy group (group A) therapy B). Glycosylated hemoglobin lipid profile tests were conducted labs...

Azilsartan medoxomil (AZL-M) is a potent angiotensin II receptor blocker that decreases blood pressure in a dose-dependent manner. It is a prodrug that is not detected in blood after its oral administration because of its rapid hydrolysis to the active moiety, azilsartan (AZL). AZL undergoes further metabolism to the major metabolite, M-II, and minor metabolites. The objective of this study was...

AIM Pridopidine, a new oral drug for treatment of patients with motor symptoms associated with Huntington's Disease (HD) is currently under development. In steady-state conditions, pridopidine elimination is mediated primarily through renal excretion. This study evaluated single dose and steady-state pharmacokinetics (PK) of a daily dose of pridopidine in subjects with mild and moderate renal i...

This report investigated safety and dosing recommendations of intravenous caspofungin in hepatic insufficiency. In the single-dose study, 8 patients each with mild and moderate hepatic insufficiency received 70 mg of caspofungin. In the multiple-dose study, 8 patients with mild hepatic insufficiency and 13 healthy matched controls received 70 mg on day 1 and 50 mg daily on days 2 through 14. Ei...

BACKGROUND There is uncertainty as to the dose of inhaled corticosteroids (ICS) at which to start concomitant long acting beta agonist (LABA) treatment in patients with asthma not adequately controlled by ICS alone. METHODS A meta-analysis was carried out of randomised, double blind clinical trials that compared the efficacy of adding salmeterol to moderate doses of ICS (fluticasone propionat...

PURPOSE The proteasome inhibitor bortezomib undergoes oxidative hepatic metabolism. This study (NCI-6432; NCT00091117) was conducted to evaluate bortezomib pharmacokinetics and safety in patients with varying degrees of hepatic impairment, to inform dosing recommendations in these special populations. EXPERIMENTAL DESIGN Patients received bortezomib on days 1, 4, 8, and 11 of 21-day cycles. P...

------------------------DOSAGE AND ADMINISTRATION--------------------- The initial dose is 40 mg once daily. After one week, increase the dose to the recommended dose of 80 mg once daily. (2.1)  Can be taken with or without food. (2.1)  The recommended dose for patients with moderate or severe hepatic impairment is 40 mg once daily. (2.2)  Consider dose reduction based on tolerability in kn...

Background: Although several treatment strategies to enhance the efficacy of electroconvulsive therapy (ECT) have been discussed, there have been no reports on the combined use of these treatments. The purpose of this study was to evaluate the efficacy and safety of concurrent use of moderate hyperventilation and a reduced dose of propofol combined with divided remifentanil in ECT practice. Met...